Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.
2.

Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts.

Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa LJ, Wu J, Devine SM, Wingard JR, Aljitawi OS, Cutler CS, Jagasia MH, Ballen KK, Eapen M, O'Donnell PV; Blood and Marrow Transplant Clinical Trials Network.

Blood. 2011 Jul 14;118(2):282-8. doi: 10.1182/blood-2011-03-344853. Epub 2011 Apr 28.

3.

Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults.

Holtick U, Albrecht M, Chemnitz JM, Theurich S, Skoetz N, Scheid C, von Bergwelt-Baildon M.

Cochrane Database Syst Rev. 2014 Apr 20;4:CD010189. doi: 10.1002/14651858.CD010189.pub2. Review.

PMID:
24748537
4.

Cost and outcome in stem cell collections in HLA-haplo identical/mismatched related transplantation with combined granulocyte-colony stimulating factor-mobilized blood and bone marrow for patients with hematologic malignancies.

Chen XH, Zhang C, Zhang X, Gao L, Gao L, Kong PY, Peng XG, Sun AH, Zeng DF, Wang QY.

Transfus Apher Sci. 2010 Aug;43(1):23-8. doi: 10.1016/j.transci.2010.05.003. Epub 2010 Jun 15.

PMID:
20554478
5.

Outpatient-based bone marrow transplantation for hematologic malignancies: cost saving or cost shifting?

Rizzo JD, Vogelsang GB, Krumm S, Frink B, Mock V, Bass EB.

J Clin Oncol. 1999 Sep;17(9):2811-8.

PMID:
10561357
6.

Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen.

Takahashi S, Ooi J, Tomonari A, Konuma T, Tsukada N, Oiwa-Monna M, Fukuno K, Uchiyama M, Takasugi K, Iseki T, Tojo A, Yamaguchi T, Asano S.

Blood. 2007 Feb 1;109(3):1322-30. Epub 2006 Oct 12.

7.

Mismatched related and unrelated donors for allogeneic hematopoietic cell transplantation for adults with hematologic malignancies.

Eapen M, O'Donnell P, Brunstein CG, Wu J, Barowski K, Mendizabal A, Fuchs EJ.

Biol Blood Marrow Transplant. 2014 Oct;20(10):1485-92. doi: 10.1016/j.bbmt.2014.05.015. Epub 2014 May 23. Review.

8.
9.

Umbilical cord blood banking: implications for perinatal care providers.

Armson BA; Maternal/Fetal Medicine Committee, Society of Obstetricians and Gynaecologists of Canada.

J Obstet Gynaecol Can. 2005 Mar;27(3):263-90. English, French. Erratum in: J Obstet Gynaecol Can. 2005 Jul;27(7):673.

PMID:
15943003
10.

Haploidentical bone marrow transplantation without T-cell depletion.

Chang YJ, Huang XJ.

Semin Oncol. 2012 Dec;39(6):653-63. doi: 10.1053/j.seminoncol.2012.09.003. Review.

PMID:
23206842
11.

Comparable long-term outcome of unrelated cord blood transplantation with related bone marrow or peripheral blood stem cell transplantation in patients aged 45 years or older with hematologic malignancies after myeloablative conditioning.

Konuma T, Kato S, Ooi J, Oiwa-Monna M, Kawamata T, Tojo A, Takahashi S.

Biol Blood Marrow Transplant. 2014 Aug;20(8):1150-5. doi: 10.1016/j.bbmt.2014.04.005. Epub 2014 Apr 13.

12.

Unrelated cord blood compared with haploidentical grafts in patients with hematological malignancies.

El-Cheikh J, Crocchiolo R, Furst S, Bramanti S, Sarina B, Granata A, Vai A, Lemarie C, Faucher C, Mohty B, Harbi S, Bouabdallah R, Vey N, Santoro A, Chabannon C, Castagna L, Blaise D.

Cancer. 2015 Jun 1;121(11):1809-16. doi: 10.1002/cncr.29271. Epub 2015 Feb 3.

PMID:
25649994
13.

Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.

Chen XH, Zhang C, Zhang X, Gao L, Gao L, Kong PY, Peng XG, Qi DG, Sun AH, Zeng DF, Liu H, Gong Y, Wang QY.

Biol Blood Marrow Transplant. 2009 Feb;15(2):266-73. doi: 10.1016/j.bbmt.2008.11.029. Erratum in: Biol Blood Marrow Transplant. 2009 Apr;15(4):521.

14.

Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies.

Takahashi S, Iseki T, Ooi J, Tomonari A, Takasugi K, Shimohakamada Y, Yamada T, Uchimaru K, Tojo A, Shirafuji N, Kodo H, Tani K, Takahashi T, Yamaguchi T, Asano S.

Blood. 2004 Dec 1;104(12):3813-20. Epub 2004 Jul 27.

15.

Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial.

Hartmann O, Le Corroller AG, Blaise D, Michon J, Philip I, Norol F, Janvier M, Pico JL, Baranzelli MC, Rubie H, Coze C, Pinna A, Méresse V, Benhamou E.

Ann Intern Med. 1997 Apr 15;126(8):600-7.

PMID:
9103126
16.

Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamide.

Munchel AT, Kasamon YL, Fuchs EJ.

Best Pract Res Clin Haematol. 2011 Sep;24(3):359-68. doi: 10.1016/j.beha.2011.05.001. Epub 2011 Jul 13.

17.
18.

Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome.

Kasamon YL, Luznik L, Leffell MS, Kowalski J, Tsai HL, Bolaños-Meade J, Morris LE, Crilley PA, O'Donnell PV, Rossiter N, Huff CA, Brodsky RA, Matsui WH, Swinnen LJ, Borrello I, Powell JD, Ambinder RF, Jones RJ, Fuchs EJ.

Biol Blood Marrow Transplant. 2010 Apr;16(4):482-9. doi: 10.1016/j.bbmt.2009.11.011. Epub 2010 Jan 18.

19.

Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia.

van Agthoven M, Groot MT, Verdonck LF, Löwenberg B, Schattenberg AV, Oudshoorn M, Hagenbeek A, Cornelissen JJ, Uyl-de Groot CA, Willemze R.

Bone Marrow Transplant. 2002 Aug;30(4):243-51.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk